Galectin Therapeutics Inc Stock Price, News & Analysis

Galectin Therapeutics (NASDAQ:GALT) presented NAVIGATE Phase 2b results for belapectin in 355 patients with compensated MASH cirrhosis and portal hypertension at AASLD 2025.

Key findings: randomization 1:1:1 to IV belapectin 2 mg/kg, 4 mg/kg or placebo every other week for 78 weeks; ELF >11.3 new varices 22.7% (2 mg/kg) vs 42.9% (placebo); Pro-C3 mean change at 78 weeks: –6.4 ng/mL (2 mg/kg) vs –4.5 ng/mL (placebo); sustained reduction in new varices persisted through 36 months (cumulative incidence 12.4% for 2 mg/kg vs 23.4% placebo). Safety profile comparable to placebo.

Galectin Therapeutics (NASDAQ: GALT) will present at the H.C. Wainwright 9th Annual MASH Virtual Investor Conference on October 21, 2025.

Company presentation is scheduled for October 21, 2025 at 7:00 AM ET, with a live webcast and archived replay available on the company’s Events & Presentations page in Investors. Management attending includes Joel Lewis, CEO, and Khurram Jamil, M.D., CMO, who will be available for one-on-one meetings during the conference; interested investors should contact their H.C. Wainwright representative to arrange meetings.

Galectin Therapeutics (NASDAQ: GALT) will present new clinical data from the NAVIGATE trial at the AASLD Liver Meeting 2025 in Washington, DC, November 7-11, 2025. The company will deliver one oral presentation and one poster highlighting belapectin results in MASH cirrhosis and portal hypertension.

Oral: "Belapectin Reduces Liver Stiffness Progression and Prevents Varices at 18 Months" on Nov 10, 2025, 2:00–3:30 PM ET (Abstract 0145). Poster: "Belapectin Maintains a Favorable Trend in Reducing Variceal Development Over 36 Months" on Nov 8, 2025, 8:00 AM–5:00 PM ET (Abstract 2375). Presentations will be viewable by AASLD attendees and posted on the company's Events & Presentations page after the congress.

Galectin Therapeutics (NASDAQ:GALT), a leader in galectin protein-targeted therapeutics, has announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York. The company's presentation is scheduled for September 8, 2025, at 1:00 PM ET.

CEO Joel Lewis and CMO Dr. Khurram Jamil will be available for one-on-one meetings during the conference. Investors can access the presentation through a live webcast, which will also be archived on the company's investor relations website.

Galectin Therapeutics (NASDAQ:GALT) reported Q2 2025 financial results and provided updates on their NAVIGATE trial for belapectin in MASH cirrhosis patients. The company ended Q2 with $13.8 million in cash and secured an additional $10 million credit line from its chairman in July 2025.

Key financial metrics include a reduced net loss of $7.6 million ($0.12 per share) compared to $12.4 million in Q2 2024, and significantly lower R&D expenses of $3.3 million vs $9.8 million year-over-year. The company presented promising NAVIGATE trial results at EASL 2025, showing sustained efficacy in reducing liver stiffness and fewer patients experiencing clinically meaningful worsening in the belapectin arm.

Galectin Therapeutics (NASDAQ:GALT) has secured a new $10 million unsecured credit line from Richard E. Uihlein, the company's Board Chairman and largest individual stockholder. The financing is expected to cover projected expenditures through June 2026.

The credit line features borrowings at the Applicable Federal Rate plus 2% (currently 6.05%), with principal and interest due September 30, 2026. The notes are convertible to common stock at the closing price on the date of each note (minimum $3.00 per share). Additionally, up to 200,000 stock purchase warrants will be issued ratably with borrowings.

Notably, the maturity dates for $111 million in existing debt from Uihlein, including three $10 million convertible notes and $81 million in credit lines, have been extended to September 30, 2026. The company continues to advance its NAVIGATE trial for belapectin in MASH cirrhosis treatment.

Galectin Therapeutics (NASDAQ:GALT) has announced a virtual KOL event scheduled for June 16, 2025, focusing on belapectin's potential in treating MASH cirrhosis and portal hypertension. The event will feature prominent experts Dr. Naga P. Chalasani from Indiana University School of Medicine and Dr. Naim Alkhouri from Summit Clinical Research. They will discuss the unmet medical needs in MASH cirrhosis treatment and present results from the NAVIGATE Phase 3 clinical trial of belapectin, a complex carbohydrate drug targeting galectin-3. Notably, belapectin could become the first approved therapy for preventing or treating varices in MASH cirrhosis, addressing a significant medical gap. The event will include presentations followed by a Q&A session.

Galectin Therapeutics (NASDAQ: GALT) reported Q1 2025 financial results and provided updates on their belapectin program. The company reported a net loss of $9.6 million ($0.15 per share), compared to $11.5 million in Q1 2024. Key highlights from the NAVIGATE trial showed that belapectin 2 mg/kg demonstrated significant improvements in liver stiffness measurements (LSM) and reduced incidence of new varices compared to placebo. The trial showed statistically significant reductions in liver stiffness at Week 26 (-3.48 kPa), Week 52 (-4.60 kPa), and Week 78 (-2.72 kPa). Notably, 51% fewer patients in the 2 mg/kg group experienced >30% worsening in liver stiffness compared to placebo. The company maintains $7.4 million in cash with an additional $11 million available through credit lines, sufficient to fund operations through August 2025.

Galectin Therapeutics (NASDAQ:GALT) presented significant results from their NAVIGATE trial for belapectin at EASL 2025 Congress. The trial evaluated belapectin, a galectin-3 inhibitor, in 287 patients with MASH cirrhosis and portal hypertension. The study demonstrated that belapectin at 2 mg/kg significantly reduced new varices by 49.3% compared to placebo (p=0.04) at 18 months in the per-protocol population. The drug also showed significant improvement in liver stiffness measurements, with the 2mg/kg dose outperforming placebo by 66% (p=0.02). The safety profile remained encouraging, with adverse events comparable to placebo and no drug-related serious adverse events reported. The trial results support belapectin's potential as a treatment for MASH cirrhosis patients with portal hypertension.